Oakworth Capital Inc. Acquires Shares of 2,774 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Oakworth Capital Inc. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 2,774 shares of the company’s stock, valued at approximately $379,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Commerce Bank increased its position in Neurocrine Biosciences by 2.6% during the 3rd quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its position in Neurocrine Biosciences by 2.7% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock valued at $496,000 after purchasing an additional 113 shares during the period. Brooklyn Investment Group increased its position in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares during the period. Tealwood Asset Management Inc. increased its position in Neurocrine Biosciences by 1.0% during the 4th quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock valued at $1,626,000 after purchasing an additional 118 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of Neurocrine Biosciences by 42.0% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after buying an additional 157 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. UBS Group upped their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Barclays upped their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.85.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 65,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. This represents a 32.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ingrid Delaet sold 272 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at $346,216.70. This trade represents a 9.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 222,693 shares of company stock worth $32,718,279 in the last quarter. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Down 0.8 %

Shares of NASDAQ:NBIX opened at $151.20 on Thursday. The firm’s 50 day moving average price is $137.92 and its 200-day moving average price is $131.51. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a market capitalization of $15.31 billion, a PE ratio of 40.54 and a beta of 0.33.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.